家族性高胆固醇血症新型药物的临床研究进展

发布时间：2018-06-12 04:14

本文选题：家族性高胆固醇血症 + PcsK9抑制剂　；参考：《重庆医科大学》2015年硕士论文

【摘要】：家族性高胆固醇血症是常染色体显性遗传疾病,主要因低密度脂蛋白受体基因突变引起血浆中低密度脂蛋白胆固醇的清除降低导致。患者从出生开始出现血浆低密度脂蛋白胆固醇显著升高引起早发冠心病。家族性高胆固醇血症早期诊断从而及时干预,可减少早发冠心病风险延长患者寿命。低密度脂蛋白胆固醇是降脂治疗中的主要干预靶点,在过去的20年里,一系列临床研究证实了他汀类药物降低低密度脂蛋白胆固醇的有效性。他汀类药物是目前家族性高胆固醇血症患者降脂治疗的首选药物,新型降脂药物PCSK9抑制剂和安塞曲匹将为低密度脂蛋白胆固醇不达标或不能耐受他汀的家族性高胆固醇血症患者提供了更多的选择。洛美他派和米泊美生由于其作用机制不依赖低密度脂蛋白受体残留功能,而对纯合子型家族性高胆固醇血症患者有效。
[Abstract]:Familial hypercholesterolemia is an autosomal dominant disease, which is mainly caused by low density lipoprotein receptor gene mutation. A significant increase in plasma low-density lipoprotein cholesterol from birth leads to early coronary heart disease. Early diagnosis of familial hypercholesterolemia and timely intervention can reduce the risk of early coronary heart disease and prolong the life span of patients. Low density lipoprotein cholesterol (LDL-C) is a major intervention target in lipid-lowering therapy. In the past 20 years, a series of clinical studies have confirmed the efficacy of statins in lowering LDL cholesterol. Statins are currently the first choice for lipid-lowering therapy in familial hypercholesterolemia patients. New lipid-lowering drugs PCSK9 inhibitors and aseptrepine will provide more options for familial hypercholesterolemia patients with low density lipoprotein cholesterol substandard or intolerant statins. Lomectadine and Mipmex are effective in patients with homozygous familial hypercholesterolemia because their mechanisms are independent of low density lipoprotein receptor residue.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R589.2

【相似文献】